Navigation Links
MannKind Updates Status of NDA Submission for AFRESA
Date:2/26/2009

VALENCIA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today provided an update on the status of its new drug application ("NDA") for AFRESA(R), an ultra rapid-acting insulin that has completed Phase 3 clinical trials. As previously announced, our internal goal was to submit the NDA to the Food and Drug Administration ("FDA") by the end of February. Based on editorial decisions made during the final stages of preparing the dossier, we have decided to extend the submission date by approximately three weeks.

The document is fully drafted. However, we decided during our final review that it would be preferable to remove several tens of thousands of pages of back-up data from the submission and instead make this material available to the FDA upon request. This change will significantly reduce the size of the NDA and should make the NDA more reviewer-friendly.

"Although I am mindful of our goal to submit the NDA as quickly as possible, it is more important to me that we provide the FDA with a high-quality submission that can be efficiently reviewed," said Dr. Peter Richardson, MannKind's Corporate Vice President and Chief Scientific Officer. "I am not willing to rush the final hyper-linking and quality-checking activities, especially when these efforts could potentially facilitate the FDA's review of our new drug application for AFRESA."

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstre
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MannKind Reports Successful Completion of Device Bioequivalence Trial
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
4. MannKind Addresses Pfizers Announcement Regarding Exubera
5. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
6. AAOMS Updates BRONJ Position Paper
7. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
8. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
11. Genmab Announces Updates on Phase III Cancer Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition of ... report to their offering. The Central Nervous ... largest segments of pharmaceuticals industry. The numbers of CNS disorders ... were unable to meet the market requirements. There has been ... especially over the past two decades. The market for CNS ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2US CNS Disorders Drug Pipeline Insight 2014 2
... Nov. 18 Disabled American Veterans (DAV) announces the launch of ... 75% and when the card is used, 50 cents will be ... , The free prescription drug cards may be used by ... a time when non-profit organizations are seeing a decline in charitable ...
... , CLEVELAND, Nov. 18 ... consumers over the counter throughout Greater Cleveland, one of two cities ... a nationwide product launch. The MyClyns spray has been used and ... years and is now available on store shelves for the very ...
Cached Medicine Technology:FREE Drug Discount Card Saves Money on Prescriptions and Raises Funds for America's Disabled Veterans 2MyClyns(R) Now Available to Greater Clevelanders 2
(Date:9/1/2014)... be able to convince your brain that healthy foods taste ... included eight overweight and obese people who were enrolled in ... react to different foods. These participants were compared to a ... in the program. Both groups had MRI brain scans ... later. The scans revealed that the people in the weight-loss ...
(Date:9/1/2014)... 2014 An operating theatre or operating ... performing surgical operations. An operating room comprises a myriad ... operating room lights, imaging displays as well as integration ... Transparency Market Research, a U.S.-based market research firm, the ... 4.5 billion by 2019. , According to this ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... Ebola drug previously given to two American aid workers successfully ... in laboratory tests, researchers report. The drug, ZMapp, prompted ... they didn,t get the medication until five days after infection. ... who were days or even hours away from death, said ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ... Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, Rn, ... of Nursing. They will be inducted with Immediate Past ... induction we reported last May. , Our three members ... 2014 American Academy of Nursing Policy Conference in Washington, ...
(Date:9/1/2014)... involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) are ... where issues related to claims involving the pain reliever ... Bernstein Liebhard LLP reports. , According to a ... the meeting is scheduled to take place on September ... of several Tylenol conferences that have taken place this ...
Breaking Medicine News(10 mins):Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4
... St. Luke,s Closure to Have Disproportionate Impact On Latinos, Other ... ... Sutter Health,s planned,closure of St. Luke,s Hospital in San Francisco ... as evidenced by new state,data released today by the California ...
... more than doubled the odds, study found , , THURSDAY, Oct. ... conditions more than double their risk of needing subsequent surgery ... was true regardless of what type of surgical technique was ... article is published in the Oct. 27 issue of ...
... lowers blood pressure might help prevent Alzheimer disease ... the most common form of dementia, is characterized by ... beta-amyloid protein. Recent evidence indicates that some drugs used ... the risk of developing AD. In a new study, ...
... PHILADELPHIA A new Center for Excellence in Ethical, ... at the University of Pennsylvania School of Medicine, a ... Sciences, the Wharton School and the Annenberg School for ... of Genetic Healthcare Technology (Penn CIGHT) will receive over ...
... of Michigan is the lead research institution in a ... the health consequences on victims in disasters. , ... Health Research, includes researchers from U-M, Dartmouth Medical School, ... University of Oklahoma. The center is funded by the ...
... prevents formation of beta-amyloid clumps in mice, study says ... pressure drug valsartan shows the ability to reduce Alzheimer,s ... value of valsartan, marketed as Diovan, emerged from a ... drugs, said study author Dr. Giulio Maria Pasinetti, a ...
Cached Medicine News:Health News:CNA Presents New Data on Sutter's Medical Redlining 2Health News:CNA Presents New Data on Sutter's Medical Redlining 3Health News:Hysterectomy May Boost Incontinence Risk 2Health News:Hysterectomy May Boost Incontinence Risk 3Health News:JCI table of contents: Oct. 25, 2007 2Health News:JCI table of contents: Oct. 25, 2007 3Health News:JCI table of contents: Oct. 25, 2007 4Health News:JCI table of contents: Oct. 25, 2007 5Health News:JCI table of contents: Oct. 25, 2007 6Health News:JCI table of contents: Oct. 25, 2007 7Health News:JCI table of contents: Oct. 25, 2007 8Health News:JCI table of contents: Oct. 25, 2007 9Health News:Penn wins $5M to start center for ethical, legal and social implications research 2Health News:Penn wins $5M to start center for ethical, legal and social implications research 3Health News:U-M to lead disaster aftermath research center 2Health News:Blood Pressure Drug Might Work Against Alzheimer's 2
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With tubular base • unit ...
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With tubular base • unit ...
Medicine Products: